STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #936 by analyst upside · 2026-09-14
PRAX
Praxis Precision Medicines, Inc.
Healthcare · Market Cap $9B · P/E 0x
ANALYST PRICE TARGET
+90.9%
implied upside to consensus target
Current Price $334.58
Consensus Target $638.68
Bull Target $1201.0
Bear Target $188.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
14
Hold
1
Sell
1
52-Week Low $37.24
52-Week High $392.7
YTD Return +16.8%
FUNDAMENTALS
Market Cap $9B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-12.96
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $37.24
52-Week High $392.7
Current Price $334.58
Bear Target $188.0
Bull Target $1201.0
● Now $334.58 ● Target $638.68
TRADING DATA
Avg Volume 442K
YTD Return +16.8%
Analyst Count 19
Consensus Buy
Upside to Target +90.9%
Last Updated 2026-09-14

ANALYST SUMMARY

Praxis Precision Medicines, Inc. (PRAX) is currently trading at $334.58 with a Wall Street consensus price target of $638.68, implying potential upside of 90.9% over the next 12 months. 19 analysts currently cover PRAX, with a consensus rating of Buy - 89% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $1201.0, while the most cautious has a target of $188.0.

PRAX operates in the Healthcare sector with a market capitalisation of $9B. The stock is up 16.8% year-to-date and is currently trading near the upper end of its 52-week range of $37.24 – $392.7.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PRAX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Goldman Sachs - Reiterated
Buy → Buy 2026-08-21 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-08-07 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-08-07 Building track record
Needham - Reiterated
Buy → Buy 2026-08-06 20% win rate (5 calls)
BTIG reit
Buy → Buy 2026-07-29 38% win rate (8 calls)
Goldman Sachs ● Initiated
Buy 2026-07-13 Building track record
Needham - Reiterated
Buy → Buy 2026-06-29 20% win rate (5 calls)
RBC Capital ● Initiated
Outperform 2026-06-18 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
23/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →